- Lilly says weight loss drug cuts heart failure risk by 38% in trial Reuters
- CrowdStrike Stock Had an Awful July. The Best Performer Might Be a Surprise. Barron’s
- Live news: Warner Music shakeup includes major promotion for son of Universal Music CEO Financial Times
- Eli Lilly says tirzepatide showed positive results in late-stage trial evaluating it as treatment for heart failure MarketWatch
- Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Investors | Eli Lilly and Company
